

Equality Impact Assessment

Preliminary assessment form v5 / 2013

www.portsmouth.gov.uk

The	preliminary	/ impact	assessment is	s a gui	ck and	easy	screening	process.	It :	shou	ld:
1110	promining	y iiiipaoi	. assessinent ic	o qui	on and	Casy	Solccining	process.	1.	JIIOU	ıu.

identify those policies, projects, services, functions or strategies which require a full EIA by
looking at:
negative positive or no impact on any of the equality groups

- opportunity to promote equality for the equality groups
- data / feedback
- prioritise if and when a full EIA should be completed
- justify reasons for why a full EIA is not going to be completed

Directorate:	Director of Public health		
Function e.g. HR, IS, carers:	Public Health		

Title of policy, service, function, project or strategy (new or old):

		,	•					
Continuin	ıg site	е						
L Rowlan	ds &	Co LTD	T/A Rowlands	Pharmacy,	129 Eastney Roa	d, Southsea	, Portsmouth,	PO4 8DZ
	• •							

Closing site

L Rowlands & Co LTD T/A Rowlands Pharmacy, 117 Winter Road, Southsea, Portsmouth, PO4 8DS

Type of policy, service, function, project or strategy:
Existing
New / proposed

Response to pharmacy consolidation application

+	Changed
	Changeu

Q1 - What is the aim of your policy, service, function, project or strategy?

To make a response to NHS England by the Health and Wellbeing Board in response to a
consolidation application of two community pharmacies as required by the NHS (Pharmaceutical
Services, Charges and Prescribing) (Amendment) Regulations 2016. Should this consolidation
application be approved, this will make a change to pharmaceutical provision in Portsmouth.

Q2 - Who is this policy, service, function, project or strategy going to benefit or have a detrimental effect on and how?

This proposed consolidation is not anticipated to have a detrimental impact on local residents as a whole, or any particular group, following consideration of access to a pharmacy, provision of pharmaceutical services and health and wellbeing needs of local residents. If approved, this pharmacy consolidation has a potential impact on individuals who currently choose to use the closing site and who will need to access an alternative pharmacy.

Q3 - Thinking about each group below, does, or could the policy, service, function, project or strategy have a negative impact on members of the equality groups below?

Group	Negative	Positive / no impact	Unclear
Age		*	
Disability		*	
Race		*	
Gender		*	
Transgender		*	
Sexual orientation		*	
Religion or belief		*	
Pregnancy and maternity		*	
Other excluded groups		*	

Q4 - Does, or could the policy, service, function, project or strategy help to promote equality for members of the equality groups?

Group	Yes	No	Unclear
Age		*	
Disability		*	
Race		*	
Gender		*	
Transgender		*	
Sexual orientation		*	
Religion or belief		*	
Pregnancy or maternity		*	
Other excluded groups		*	

If the answer is "no" or "unclear" consider doing a full EIA

Q5 - Do you have any feedback data from the equality groups that influences, affects or shapes this policy, service, function, project or strategy?

Group	Yes	No	Unclear
Age		*	
Disability		*	
Race		*	
Gender		*	
Transgender		*	
Sexual orientation		*	

Religion or belief	*	
Pregnancy and maternity	*	
Other excluded groups	*	

If the answer is "no" or "unclear" consider doing a full EIA

Q6 - Using the assessments in questions 3, 4 and 5 should a full assessment be carried out on this policy, service, function or strategy?

yes	*	No
•		

Q7 - How have you come to this decision?

This conclusion has been informed by the Portsmouth Pharmaceutical Needs Assessment (PNA) 2015 (which is the current PNA and included extensive information gathering and consultation) and by the information provided in the pharmacy consolidation application.

The consolidation application states that the closing site is quiet with a significant proportion receiving compliance aids (known as monitored dosage system (MDS) packs). While individuals may choose to use a regular pharmacy, individuals can access any pharmacy for dispensing of prescriptions, over the counter medicine sales and for other pharmaceutical services, for which there will be no change in provision of services. The current PNA concludes that there is good pharmaceutical provision in Portsmouth. This would not change to any notably extent should this consolidation application be approved.

The consolidation application also states that MDS packs currently are, and will be provided at the continuing site. It should be noted that provision of MDS packs is not an essential service for any pharmacy. If a pharmacy has a patient that is covered by the Equality Act then the pharmacy has to consider what reasonable adjustment it might make to help the patient to make use of its services. An MDS is just one possibility but there are many others including use of reminder charts, large print labels, information sheets, reminder alarms, among others. Furthermore, in general, there is insufficient evidence to support widespread use of MDS packs in improving medicines adherence in patients. A MDS pack may be of value for some patients whose needs have been assessed on an individual basis with any intervention tailored to the patient's specific requirements.

The Royal Pharmaceutical Society provides guidance on this:

http://psnc.org.uk/wp-content/uploads/2017/08/PSNC-Briefing-060.17-Equality-Act-2010-A-quick-reference-guide-Sep-2017-update.pdf

https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Support/toolkit/rps-mca-july-2013.pdf

Both sites have access for wheelchair users and access without steps. The application states there is an induction loop at the continuing site currently which will not continue to be in place. NHS England should clarify whether this information is correct.

No specific impact from the proposed consolidation has been identified following consideration of potential impacts on access to a pharmacy and provision of pharmaceutical services and based on the demography, health and wellbeing needs of local residents which are summarised in the accompanying paper.

If you have to complete a full EIA please contact the Equalities and diversity team if you require help Tel: 023 9283 4789 or email:equalities@portsmouthcc.gov.uk

OR -	Who	vas inv	olved i	n the	FIA?
WO -	VVIIC	vas IIIv	uiveu i	II LIIE	LIA:

Claire Currie, Consultant in Public Health					

This EIA has been approved by: Dr Jason Horsley

Contact number: 023 9284 1779

Date: 16/11/17

Please email a copy of your completed EIA to the Equality and diversity team. We will contact you with any comments or queries about your preliminary EIA.

Telephone: 023 9283 4789

Email: equalities@portsmouthcc.gov.uk